You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

RELAFEN Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Relafen patents expire, and when can generic versions of Relafen launch?

Relafen is a drug marketed by Smithkline Beecham and is included in one NDA.

The generic ingredient in RELAFEN is nabumetone. There are twenty drug master file entries for this compound. Twenty-five suppliers are listed for this compound. Additional details are available on the nabumetone profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Relafen

A generic version of RELAFEN was approved as nabumetone by CHARTWELL RX on February 25th, 2002.

  Try a Trial

Drug patent expirations by year for RELAFEN
Drug Sales Revenue Trends for RELAFEN

See drug sales revenues for RELAFEN

Recent Clinical Trials for RELAFEN

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Sanford ResearchEarly Phase 1
Dr. Reddy's Laboratories LimitedPhase 1

See all RELAFEN clinical trials

US Patents and Regulatory Information for RELAFEN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Smithkline Beecham RELAFEN nabumetone TABLET;ORAL 019583-001 Dec 24, 1991 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Smithkline Beecham RELAFEN nabumetone TABLET;ORAL 019583-002 Dec 24, 1991 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for RELAFEN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Smithkline Beecham RELAFEN nabumetone TABLET;ORAL 019583-001 Dec 24, 1991 ⤷  Try a Trial ⤷  Try a Trial
Smithkline Beecham RELAFEN nabumetone TABLET;ORAL 019583-001 Dec 24, 1991 ⤷  Try a Trial ⤷  Try a Trial
Smithkline Beecham RELAFEN nabumetone TABLET;ORAL 019583-002 Dec 24, 1991 ⤷  Try a Trial ⤷  Try a Trial
Smithkline Beecham RELAFEN nabumetone TABLET;ORAL 019583-002 Dec 24, 1991 ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for RELAFEN

See the table below for patents covering RELAFEN around the world.

Country Patent Number Title Estimated Expiration
United Kingdom 1474377 ⤷  Try a Trial
Hong Kong 56280 4-(6'-METHOXY-2'-NAPHTHYL)-BUTAN-2-ONE ⤷  Try a Trial
Denmark 156642 ⤷  Try a Trial
Denmark 477674 ⤷  Try a Trial
Sweden 420598 ANALOGIFORFARANDE FOR FRAMSTELLNING AV NAFTALENDERIVAT ⤷  Try a Trial
Switzerland 603525 ⤷  Try a Trial
Japan S5053359 ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.